ArticleFrontiers in bioengineering and biotechnology2025
"Live" cell shipment-a forward-looking transport option for cryo-sensitive cell-based therapies.
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell therapies, which use the transplantation or manipulation of cells to treat diseases, are highly promising for conditions such as cancer, autoimmune diseases, and genetic disorders. Their success depends on the quality and viability of the administered cell products, which is especially critical for patients already weakened by chemotherapy or radiation. In such cases, ensuring high-quality cells that can engraft, proliferate, and function properly is essential for improving outcomes and survival. Natural killer (NK) cells are strong candidates for cancer treatment due to their innate cytotoxic activity without the side effects of graft-versus-host disease (GvHD). However, cryopreservation has significantly hindered their clinical application, as it reduces both survival and function. Current "off-the-shelf" allogeneic NK therapies, therefore, face limitations because freezing and thawing lead to cell loss and impaired activity. To address this challenge, we evaluated live shipment of NK cells using the Cellbox™ Shipper Flight, a transportable incubator maintaining 37°C and 5% CO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.